title: A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.
authors.forename: J M
authors.initials: JM
authors.lastname: Brandwein
authors.forename: L
authors.initials: L
authors.lastname: Yang
authors.forename: A D
authors.initials: AD
authors.lastname: Schimmer
authors.forename: A C
authors.initials: AC
authors.lastname: Schuh
authors.forename: V
authors.initials: V
authors.lastname: Gupta
authors.forename: R A
authors.initials: RA
authors.lastname: Wells
authors.forename: S M H
authors.initials: SM
authors.lastname: Alibhai
authors.forename: W
authors.initials: W
authors.lastname: Xu
authors.forename: M D
authors.initials: MD
authors.lastname: Minden
mesh_terms: D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D015254:DNA Modification Methylases / Q000378:metabolism*; D045643:DNA Repair Enzymes / Q000378:metabolism*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008875:Middle Aged; D011237:Predictive Value of Tests; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide